Shortlist

EV/EBIT of 7.0 against a Healthcare median of 22.1 — 68% below peers. Free cash flow yield 14.3%. Trading 73% below its all-time high set 2000-08-25.

At the Healthcare median EV/EBIT of 22.1 instead of its current 7.0, and with earnings unchanged, the equity would be worth about 233% more. That is the size of the gap, not a forecast that it closes.

• ROIC 760% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 48% over three years
• net debt 0.5x EBITDA — balance sheet not forcing anything

Consensus strong buy from 11 analysts, mean target 20.82 USD, 136% above the current price. No revision activity in the last quarter.

Targets spread 96% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Implied upside of 136% is unusually high. The evidence runs the other way here: stocks with the most optimistic targets tend to underperform, because the optimism bias is real and priced-in slowly. Read this as a caution, not an opportunity.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 11.8 against a Consumer Cyclical median of 17.8 — 34% below peers. Free cash flow yield 9.2%. Trading 42% below its all-time high set 2018-09-27.

At the Consumer Cyclical median EV/EBIT of 17.8 instead of its current 11.8, and with earnings unchanged, the equity would be worth about 51% more. That is the size of the gap, not a forecast that it closes.

• ROIC 51% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• net debt 0.0x EBITDA — balance sheet not forcing anything
• Altman Z 9.7 — outside the distress zone

Consensus buy from 12 analysts, mean target 41.50 USD, 28% above the current price. No revision activity in the last quarter.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 24.1 against a Technology median of 26.9 — 10% below peers. Free cash flow yield 5.5%. Trading 40% below its all-time high set 2021-08-25.

At the Technology median EV/EBIT of 26.9 instead of its current 24.1, and with earnings unchanged, the equity would be worth about 11% more. That is the size of the gap, not a forecast that it closes.

• ROIC 40% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 13% over three years
• net debt 0.1x EBITDA — balance sheet not forcing anything

Consensus strong buy from 34 analysts, mean target 314.57 USD, 52% above the current price. No revision activity in the last quarter.

Targets spread 75% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 11.3 against a Technology median of 26.9 — 58% below peers. Free cash flow yield 9.7%. Trading 63% below its all-time high set 2021-11-19.

At the Technology median EV/EBIT of 26.9 instead of its current 11.3, and with earnings unchanged, the equity would be worth about 138% more. That is the size of the gap, not a forecast that it closes.

• ROIC 63% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 11% over three years
• net debt 0.0x EBITDA — balance sheet not forcing anything

Consensus hold from 34 analysts, mean target 270.61 USD, 6% above the current price. Revisions over the last quarter have been net negative — the sell side is marking this down.

Targets spread 70% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 7.7 against a Technology median of 26.9 — 71% below peers. Free cash flow yield 11.4%. Trading 69% below its all-time high set 2021-11-15.

At the Technology median EV/EBIT of 26.9 instead of its current 7.7, and with earnings unchanged, the equity would be worth about 233% more. That is the size of the gap, not a forecast that it closes.

• ROIC 17% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 11% over three years
• net debt -0.4x EBITDA — balance sheet not forcing anything
• Altman Z 4.9 — outside the distress zone

Consensus buy from 13 analysts, mean target 125.85 USD, 27% above the current price. Revisions over the last quarter are balanced.

Targets spread 56% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 0.4 against a Technology median of 26.9 — 99% below peers. Free cash flow yield 186.8%. Trading 86% below its all-time high set 2000-03-03.

At the Technology median EV/EBITDA of 18.4 instead of its current 0.3, and with earnings unchanged, the equity would be worth about n/a more. That is the size of the gap, not a forecast that it closes.

• ROIC 33% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 8/9 — accounts improving year on year
• net debt -0.3x EBITDA — balance sheet not forcing anything
• operating margin 17%

mean target 9.67 SEK, 4% below the current price. No revision activity in the last quarter.

Targets spread 35% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Trading 4% above the consensus target — the sell side thinks it is expensive.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 7.0 against a Consumer Defensive median of 16.6 — 58% below peers. Free cash flow yield 13.8%. Trading 50% below its all-time high set 2004-04-21.

At the Consumer Defensive median EV/EBIT of 16.6 instead of its current 7.0, and with earnings unchanged, the equity would be worth about 103% more. That is the size of the gap, not a forecast that it closes.

• ROIC 35% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 7% over three years
• net debt -1.9x EBITDA — balance sheet not forcing anything

mean target 44.00 USD, 33% above the current price. No revision activity in the last quarter.

Only 1 analyst estimate(s) — too few for a consensus to mean much.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 4.1 against a Financial Services median of 8.5 — 52% below peers. Free cash flow yield 25.8%. Trading 60% below its all-time high set 2025-06-09.

At the Financial Services median EV/EBIT of 8.5 instead of its current 4.1, and with earnings unchanged, the equity would be worth about 53% more. That is the size of the gap, not a forecast that it closes.

• ROIC 144% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 30% over three years
• net debt -4.0x EBITDA — balance sheet not forcing anything
• Altman Z 13.0 — outside the distress zone

Consensus buy from 14 analysts, mean target 48.43 USD, 58% above the current price. No revision activity in the last quarter.

Targets spread 118% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

P/E of 2.2 against a Communication Services median of 14.5 — 85% below peers.

No usable re-rating gap: the multiple is at or above its sector median, or the inputs were missing.

• ROIC 692% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 5% over three years
• net debt -4.1x EBITDA — balance sheet not forcing anything

Consensus strong buy from 32 analysts, mean target 161.33 CNY, 39% above the current price. No revision activity in the last quarter.

Targets spread 42% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 17.3 against a Technology median of 26.9 — 36% below peers. Free cash flow yield 6.9%. Trading 61% below its all-time high set 2025-07-30.

At the Technology median EV/EBIT of 26.9 instead of its current 17.3, and with earnings unchanged, the equity would be worth about 56% more. That is the size of the gap, not a forecast that it closes.

• ROIC 19% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 9/9 — accounts improving year on year
• revenue compounding at 14% over three years
• net debt 0.4x EBITDA — balance sheet not forcing anything

Consensus buy from 33 analysts, mean target 446.02 USD, 42% above the current price. Revisions over the last quarter have been net negative — the sell side is marking this down.

Targets spread 150% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 6.0 against a Consumer Defensive median of 16.6 — 64% below peers. Free cash flow yield 6.7%. Trading 42% below its all-time high set 2025-04-23.

At the Consumer Defensive median EV/EBIT of 16.6 instead of its current 6.0, and with earnings unchanged, the equity would be worth about 247% more. That is the size of the gap, not a forecast that it closes.

• ROIC 19% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• net debt 1.3x EBITDA — balance sheet not forcing anything
• Altman Z 3.4 — outside the distress zone

Consensus hold from 7 analysts, mean target 33.64 USD, 11% above the current price. No revision activity in the last quarter.

Targets spread 42% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 6.4 against a Financial Services median of 8.5 — 24% below peers. Free cash flow yield 14.3%.

At the Financial Services median EV/EBIT of 8.5 instead of its current 6.4, and with earnings unchanged, the equity would be worth about 27% more. That is the size of the gap, not a forecast that it closes.

• ROIC 54% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 31% over three years
• operating margin 19%

mean target 150.00 ILS, 24% below the current price. Revisions over the last quarter are balanced.

Only 1 analyst estimate(s) — too few for a consensus to mean much.

Trading 24% above the consensus target — the sell side thinks it is expensive.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.